Comparative Pharmacology
Head-to-head clinical analysis: KETOZOLE versus MICONAZOLE 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOZOLE versus MICONAZOLE 7.
KETOZOLE vs MICONAZOLE 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
200 mg orally once daily with food.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Primarily fecal (~50%) and renal (~<1% unchanged)
Category C
Category A/B
Antifungal
Antifungal